Overview

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Status:
Recruiting
Trial end date:
2022-03-02
Target enrollment:
Participant gender:
Summary
The aim of this study is to understand how TAK-906 tablets and capsules are processed by the body in healthy adults under fasting conditions and also how TAK-906 tablets are processed by the body when taken with a high fat high calorie breakfast compared to fasting. This study will require participants to stay at the clinical research unit for about 3 weeks to be monitored after receiving TAK-906.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda